Publication | Open Access
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
46
Citations
37
References
2021
Year
The early atherosclerotic lesion size was less visible in empagliflozin-treated mice. Empagliflozin could decrease lipid profiles and sympathetic activity in atherosclerosis.
| Year | Citations | |
|---|---|---|
Page 1
Page 1